A new study from Case Western Reserve University has found that inflammatory sugars produced by gut bacteria may trigger ALS and frontotemporal dementia in genetically at-risk individuals, with clinical trials potentially a year away.
A study published in Nature by researchers at the Weizmann Institute of Science has identified a mechanism by which gut bacteria may determine why some carriers of the C9orf72 mutation — the most common genetic cause of both ALS and frontotemporal dementia (FTD) — develop the diseases while others remain healthy. Using mouse models and human patient samples, the team found that specific gut bacteria produce a modified form of glycogen that triggers neuroinflammation, offering a concrete environmental explanation for the incomplete penetrance that has long puzzled researchers studying these mutations.
The researchers demonstrated that harmful gut bacteria synthesize an inflammatory form of glycogen — a branched sugar molecule — that activates immune pathways in the brain. In ALS/FTD patients carrying the C9orf72 mutation, levels of this bacterial glycogen were significantly elevated compared to healthy controls. When the team reduced these harmful bacterial sugars in mouse models, either through antibiotics or dietary intervention, they observed reduced neuroinflammation and extended lifespan, suggesting the gut-brain axis plays a direct role in disease onset.
We've explored broader connections between gut bacteria and neurological function in a recent video on our YouTube channel.
For anyone paying attention to the growing body of science linking gut health to brain function, this study adds weight to what was once a fringe idea. What we eat, the bacteria we harbor, and the biochemical environment of our digestive systems appear to play a direct role in whether certain neurological diseases take hold. It's a finding that puts gut health squarely in the conversation about disease prevention — not just digestion or comfort — and raises the possibility that interventions targeting the microbiome could one day help protect those most genetically vulnerable to ALS and FTD.
